BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Surzetoclax readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Surzetoclax\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06291220-3279@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Surzetoclax: Phase 1 readout est. (NCT06291220)
DESCRIPTION:Surzetoclax\, phase 1.\nStudy: A Study Assessing Adverse Event 
 and How Oral ABBV-453 Moves Through the Body in Adult Participants With Re
 lapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lympho
 cytic Lymphoma (SLL)\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/surzetoclax#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06291220
URL:https://assetmemo.bio/drug/surzetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-3279@assetmemo.bio
DTSTAMP:20261121T005933Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Surzetoclax: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Surzetoclax\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to 
 Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax A
 lone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in
  Adult Participants With Multiple Myeloma (MM)\nEstimated primary completi
 on: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 rzetoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06953960
URL:https://assetmemo.bio/drug/surzetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
